🇺🇸 FDA
Patent

US 12234460

Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors

granted A61KA61K31/4535A61K31/565

Quick answer

US patent 12234460 (Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/4535, A61K31/565, A61K31/57, A61K31/663